Published in Oncogene on March 06, 2003
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
MEK and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.90
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One (2009) 1.84
Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell (2010) 1.72
Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol (2005) 1.51
Protein kinase C iota: human oncogene, prognostic marker and therapeutic target. Pharmacol Res (2007) 1.42
MEK5/ERK5 pathway: the first fifteen years. Biochim Biophys Acta (2011) 1.39
Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev Biol (2003) 1.36
Regulation of the G2-M cell cycle progression by the ERK5-NFkappaB signaling pathway. J Cell Biol (2007) 1.36
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
A kinase shRNA screen links LATS2 and the pRB tumor suppressor. Genes Dev (2011) 1.30
Mechanism of human dermal fibroblast migration driven by type I collagen and platelet-derived growth factor-BB. Mol Biol Cell (2003) 1.29
Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). Neoplasia (2008) 1.17
Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Breast Cancer Res (2010) 1.14
Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis. Oncogene (2011) 1.13
ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer (2011) 1.10
IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer (2014) 1.08
Activation of the MEK5/ERK5 cascade is responsible for biliary dysgenesis in a rat model of Caroli's disease. Am J Pathol (2005) 1.03
Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res (2011) 1.02
A comparison of epithelial-to-mesenchymal transition and re-epithelialization. Semin Cancer Biol (2012) 1.00
The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer (2009) 0.99
PAK1 regulates breast cancer cell invasion through secretion of matrix metalloproteinases in response to prolactin and three-dimensional collagen IV. Mol Endocrinol (2013) 0.97
Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. Br J Cancer (2013) 0.93
Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1. ACS Med Chem Lett (2011) 0.92
BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction. Oncogene (2012) 0.92
Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. Br J Cancer (2007) 0.92
Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas. Clin Cancer Res (2013) 0.89
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorg Med Chem Lett (2011) 0.89
Canonical and kinase activity-independent mechanisms for extracellular signal-regulated kinase 5 (ERK5) nuclear translocation require dissociation of Hsp90 from the ERK5-Cdc37 complex. Mol Cell Biol (2013) 0.88
Erk5 contributes to maintaining the balance of cellular nucleotide levels and erythropoiesis. Cell Cycle (2015) 0.88
X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor. J Med Chem (2013) 0.86
Expression of the phosphorylated MEK5 protein is associated with TNM staging of colorectal cancer. BMC Cancer (2012) 0.85
Targeting RTK Signaling Pathways in Cancer. Cancers (Basel) (2015) 0.85
ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells. J Cell Physiol (2014) 0.85
Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. J Biomol Screen (2012) 0.84
MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. PLoS One (2013) 0.84
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. Cell Cycle (2016) 0.84
Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. Cell Death Dis (2015) 0.82
Identification and validation of dysregulated MAPK7 (ERK5) as a novel oncogenic target in squamous cell lung and esophageal carcinoma. BMC Cancer (2015) 0.82
ERK5/BMK1 is a novel target of the tumor suppressor VHL: implication in clear cell renal carcinoma. Neoplasia (2013) 0.82
Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production. Oncol Lett (2013) 0.82
Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L. Oncotarget (2015) 0.80
Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones. Eur J Med Chem (2013) 0.80
Role of p90(RSK) in regulating the Crabtree effect: implications for cancer. Biochem Soc Trans (2013) 0.79
The novel lupus antigen related protein acheron enhances the development of human breast cancer. Int J Cancer (2011) 0.79
E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis. Oncotarget (2014) 0.78
Loss of endothelial cell-specific molecule 1 promotes the tumorigenicity and metastasis of prostate cancer cells through regulation of the TIMP-1/MMP-9 expression. Oncotarget (2017) 0.78
Mitogen/extracellular signal-regulated kinase kinase-5 promoter region polymorphisms affect the risk of sporadic colorectal cancer in a southern Chinese population. DNA Cell Biol (2011) 0.77
4-isothiocyanate-2, 2, 6, 6-tetramethyl piperidinooxyl inhibits angiogenesis by suppressing VEGFR2 and Tie2 phosphorylation. Oncol Lett (2016) 0.75
Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. Sci Rep (2017) 0.75
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Mol Cell Proteomics (2017) 0.75
Phosphorylation of BMK1 induces prostatic carcinoma cell proliferation by promoting entry into the S phase of the cell cycle. Oncol Lett (2015) 0.75
Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity. Biochem Biophys Res Commun (2015) 0.75
MEK5 overexpression is associated with the occurrence and development of colorectal cancer. BMC Cancer (2016) 0.75
Discovery of a novel allosteric inhibitor-binding site in ERK5: comparison with the canonical kinase hinge ATP-binding site. Acta Crystallogr D Struct Biol (2016) 0.75
Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity. Sci Rep (2017) 0.75
Increased T cell infiltration elicited by Erk5 deletion in a Pten-deficient mouse model of prostate carcinogenesis. Cancer Res (2017) 0.75
A comparison of pre-operative nerve stimulator-guided femoral nerve block and fascia iliaca compartment block in patients with a femoral neck fracture. Anaesthesia (2013) 6.65
High resolution cosmid and P1 maps spanning the 14 Mb genome of the fission yeast S. pombe. Cell (1993) 3.56
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol (2000) 2.73
Identification of residues in the human DNA repair enzyme HAP1 (Ref-1) that are essential for redox regulation of Jun DNA binding. Mol Cell Biol (1993) 2.73
Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci (2001) 2.64
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Screening for prostate cancer in the UK. Seems to be creeping in by the back door. BMJ (2001) 2.22
Ambulatory urodynamics. Br J Urol (1996) 2.06
Complete coverage of the Schizosaccharomyces pombe genome in yeast artificial chromosomes. Nat Genet (1992) 1.93
Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev (2006) 1.93
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
Evaluation of culture and the Gen-Probe PACE 2 assay for detection of Neisseria gonorrhoeae and Chlamydia trachomatis in endocervical specimens transported to a state health laboratory. J Clin Microbiol (1992) 1.76
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol (1998) 1.76
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
Identification of critical active-site residues in the multifunctional human DNA repair enzyme HAP1. Nat Struct Biol (1995) 1.68
Tip60 is a nuclear hormone receptor coactivator. J Biol Chem (1999) 1.67
Written consent about sexual function in men undergoing transurethral prostatectomy. Br J Urol (1994) 1.65
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate (1998) 1.61
A retrospective review of a large cohort of patients undergoing the process of withholding or withdrawal of life support. Crit Care Med (1997) 1.58
Skin carriage of acinetobacters in Hong Kong. J Clin Microbiol (1999) 1.53
Bladder function in healthy volunteers: ambulatory monitoring and conventional urodynamic studies. Br J Urol (1994) 1.51
Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. Br J Urol (1995) 1.50
Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol (1995) 1.49
Screening for bacteriuria in urological patients using reagent strips. Br J Urol (1992) 1.48
p53 and p53-regulated genes in bladder cancer. Br J Urol (1998) 1.46
Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol (2007) 1.46
Mucin gene expression in human urothelium and in intestinal segments transposed into the urinary tract. J Urol (2000) 1.45
Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28. Int Immunol (1998) 1.44
Amplification and increased expression of alpha class glutathione S-transferase-encoding genes associated with resistance to nitrogen mustards. Proc Natl Acad Sci U S A (1988) 1.43
Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem (1988) 1.43
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med (2016) 1.41
Pearls from geriatrics, or a long line at the bathroom. J Fam Pract (1995) 1.40
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. Br J Cancer (1991) 1.39
The effect of prostatectomy on symptom severity and quality of life. Br J Urol (1996) 1.39
Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol (2000) 1.38
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. Br J Cancer (2001) 1.37
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Site-directed mutagenesis of the human DNA repair enzyme HAP1: identification of residues important for AP endonuclease and RNase H activity. Nucleic Acids Res (1995) 1.34
Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression. Oncogene (2009) 1.33
Rectal, bladder and sexual function after mucosal proctectomy with and without a pelvic reservoir for colitis and polyposis. Br J Surg (1982) 1.33
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol (1996) 1.30
Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer (1987) 1.30
A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study. J Urol (2000) 1.27
Characterization of whole genome radiation hybrid mapping resources for non-mammalian vertebrates. Nucleic Acids Res (1998) 1.23
The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Pathol (2008) 1.22
Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev (2006) 1.21
Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int (2000) 1.21
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene (1999) 1.21
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer (2005) 1.20
β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene (2010) 1.20
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer (2006) 1.19
UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer (2009) 1.18
Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol (1999) 1.17
Reconstitution of RecBC DNase activity from purified Escherichia coli RecB and RecC proteins. J Biol Chem (1985) 1.16
Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death Dis (2011) 1.15
Lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer. Oncogene (2006) 1.14
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol (2004) 1.14
Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol (2005) 1.14
Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene (2007) 1.13
Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial. J Urol (2001) 1.12
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer (2010) 1.12
ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer (2011) 1.10
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev (2003) 1.08
Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability. J Urol (1996) 1.08
Tip60 is a co-activator specific for class I nuclear hormone receptors. J Biol Chem (2001) 1.07
BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol (2008) 1.07
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. J Urol (2001) 1.07
Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene (2001) 1.07
The National Prostatectomy Audit: the clinical management of patients during hospital admission. Br J Urol (1995) 1.07
The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine (1999) 1.06
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol (1992) 1.06
P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol (1992) 1.05
Immunohistochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol (1991) 1.05
Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology (2004) 1.05
Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res (1989) 1.04
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer (1996) 1.03
Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. Health Technol Assess (2012) 1.03
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer (1996) 1.03
Epididymectomy is an effective treatment for scrotal pain after vasectomy. BJU Int (2000) 1.03
Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study. Eur Urol (1996) 1.02
Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis (2010) 1.02